Fintel reports that on October 29, 2025, Truist Securities reiterated coverage of Incyte (NasdaqGS:INCY) with a Hold recommendation. Analyst Price Forecast Suggests 2.86% Downside As of October 28, ...

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion. Total revenues increased 20% year over year, primarily driven by a rise in ...

Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 ...

Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now. Wells Fargo upgraded Incyte Corporation (NASDAQ:INCY) to Overweight from Equal Weight on August 6, ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Incyte (NasdaqGS:INCY) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.78% Upside As of August 6, 2025, ...

- Pipeline data presented includes data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD ...

Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed yesterday at $68.30. Leverage the power of TipRanks' Smart ...

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of Pim ...